BCIQ Profiles

Company Profile Report

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology.

Swedish Orphan Biovitrum AB (SSE:SOBI) will acquire Dova

Read the full 375 word article

How to gain access

Continue reading with a
two-week free trial.